Zymeworks Announces Participation in Upcoming Investor Conferences
May 02 2022 - 8:30AM
Business Wire
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical
company developing next-generation multifunctional biotherapeutics,
today announced that management will participate in an upcoming
investor conference:
- H.C. Wainwright Global Investment Conference. Zymeworks
will participate virtually in one-on-one meetings on May 24th –
26th and a corporate presentation will be available virtually on
May 24th at 7 a.m. ET.
The presentation will be available on Zymeworks’ website at
http://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company
dedicated to the discovery, development and commercialization of
next-generation multifunctional biotherapeutics. Zymeworks’ suite
of therapeutic platforms and its fully integrated drug development
engine enable precise engineering of highly differentiated product
candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a
novel Azymetric™ HER2-targeted bispecific antibody currently being
evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials
globally as a targeted treatment option for patients with solid
tumors that express HER2. Zymeworks’ second clinical candidate,
ZW49, is a novel bispecific HER2‑targeted antibody-drug conjugate
currently in Phase 1 clinical development and combines the unique
design and antibody framework of zanidatamab with Zymeworks’
proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also
advancing a deep preclinical pipeline in oncology (including
immuno-oncology agents) and other therapeutic areas. In addition,
its therapeutic platforms are being leveraged through strategic
partnerships with global biopharmaceutical companies. For more
information on our ongoing clinical trials visit
www.zymeworksclinicaltrials.com. For additional information about
Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220502005052/en/
Investor Inquiries: Jack Spinks (604) 678-1388
ir@zymeworks.com
Media Inquiries: Diana Papove (604) 678-1388
media@zymeworks.com
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From Apr 2024 to May 2024
Zymeworks (NYSE:ZYME)
Historical Stock Chart
From May 2023 to May 2024